ALK and non-small cell lung carcinoma: With the FDA approval of brigatinib for the treatment of crizotinib-resistant, ALK-positive NSCLC (with orphan drug designation for ALK+ NSCLC) in April 2017, there are now 4 drugs available for the treatment of ALK-positive NSCLC.